Silo Pharma, Inc.

Announcement of Cryptocurrency Treasury Strategy and Formation of Cypto Advisory Board.

On August 4, 2025, our Board of Directors (“Board”) approved the establishment of a cryptocurrency advisory board (the “Crypto Advisory Board”) which will initially consist of up to three (3) members in connection with our Company’s cryptocurrency treasury strategy focused on leading digital assets, including Bitcoin, Ethereum, and Solana. On August 4, 2025. the Board appointed Corwin Yu as the initial member of the Crypto Advisory Board.

On August 5, 2025, we announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets.

Director and Officer Trading Arrangements

During our quarter ended June 30, 2025, none of our directors or executive officers adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K of the Exchange Act.

Nasdaq Minimum Bid Price Deficiency Notice

On June 27, 2025, the Company received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Company was provided 180 calendar days, or until December 24, 2025, to regain compliance. The notice has no immediate effect on the listing of the Company’s common stock, which will continue to trade under the symbol “SILO”. The Company is monitoring the bid price of its common stock and may consider available options to regain compliance, including a reverse stock split, if necessary.

-34-